US 11,867,696 B2
Antigen-coupled immunoreagents
David A. Schwartz, Encinitas, CA (US)
Assigned to CELL IDX, INC., San Diego, CA (US)
Filed by CELL IDX, INC., San Diego, CA (US)
Filed on Feb. 6, 2016, as Appl. No. 15/017,626.
Claims priority of provisional application 62/247,415, filed on Oct. 28, 2015.
Claims priority of provisional application 62/113,141, filed on Feb. 6, 2015.
Prior Publication US 2016/0258956 A1, Sep. 8, 2016
Int. Cl. G01N 33/00 (2006.01); G01N 33/535 (2006.01); G01N 33/574 (2006.01); G01N 33/533 (2006.01); C07K 16/44 (2006.01); C07K 16/00 (2006.01); G01N 33/543 (2006.01)
CPC G01N 33/5743 (2013.01) [C07K 16/00 (2013.01); C07K 16/44 (2013.01); G01N 33/533 (2013.01); G01N 33/535 (2013.01); G01N 33/54306 (2013.01); G01N 33/574 (2013.01); G01N 2474/20 (2021.08); G01N 2800/60 (2013.01)] 28 Claims
OG exemplary drawing
 
1. An immunoreagent composition comprising:
a primary antibody coupled to a bridging antigen, said bridging antigen comprising a peptide consisting of a sequence selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, and SEQ ID NO: 8; and
a detectable secondary antibody;
wherein the detectable secondary antibody is a rabbit monoclonal antibody specific for said peptide.